Two patients stopped antiretroviral drugs and kept the virus at bay
In a Paris laboratory, a small but significant trial has offered a new way of imagining life with HIV — not as a condition requiring daily medication forever, but as one that might be brought under lasting control by the body's own retrained defenses. Six patients received CAR-T cell therapy, in which their immune cells were engineered to hunt the virus and returned to their bodies; two have now lived without antiretroviral drugs for up to two years, their viral loads silent or nearly so. The approach does not yet constitute a cure, but it represents a meaningful turn in the long human effort to move HIV from a lifelong sentence to a manageable, and perhaps one day conquerable, condition. For the 41 million people worldwide who currently depend on daily medication, this early work carries the weight of genuine possibility.
- Two patients in a Phase 1 trial have gone over a year — one nearly two — without antiretroviral drugs while keeping HIV undetectable, a result that has quietly electrified the research community.
- The trial was small and designed for safety, not proof of efficacy, meaning the uneven outcomes across six patients raise as many questions as they answer.
- Unlike previous HIV 'cures' that depended on rare donor genetics and bone marrow transplants, this approach uses each patient's own cells — a design built from the start with accessibility and affordability in mind.
- Researchers have identified early diagnosis and rapid treatment initiation as likely keys to success, suggesting the therapy works best when the virus has had less time to mutate and entrench itself.
- Side effects were notably milder than in cancer applications of CAR-T, offering cautious optimism that the therapy could be tolerated more broadly as trials expand.
In a Paris laboratory, researchers have taken a different path toward controlling HIV — not through daily pills, but by rewiring patients' own immune cells to hunt the virus. They extracted T-cells from six participants, engineered them to recognize two specific entry points on HIV, multiplied them in the lab, and reinfused them. Two of those patients have since stopped antiretroviral therapy entirely, one for more than two years and another for nearly a year, with viral loads remaining undetectable or barely measurable. It is a Phase 1 safety trial, small and preliminary, but it marks a genuine shift in how scientists are approaching one of the world's most persistent infections.
The therapy — known as CAR-T — is not new to medicine. It has been used for years against blood cancers, where it can produce powerful but sometimes dangerous inflammatory responses. In this HIV trial, side effects were considerably milder, likely because the viral burden is lower than a tumor burden and the immune assault required is less fierce. That relative tolerability matters for a disease affecting 41 million people globally.
What distinguishes this approach from earlier HIV cure attempts is its potential reach. Previous successes involved bone marrow transplants from donors carrying a rare genetic mutation that confers natural HIV resistance — a path available only to a vanishingly small number of patients. CAR-T uses each person's own cells, and the nonprofit collaborating on the trial has stated explicitly that affordability and accessibility are central goals.
The results across the six participants were uneven. Of those who received the full dose, two have fared remarkably well; a third experienced a viral rebound before stabilizing at low but detectable levels. Lead investigator Dr. Steven Deeks observed that the patients who responded best had been diagnosed and started on antiretroviral therapy quickly after infection — a finding that points toward early treatment as a possible prerequisite for success, since it may leave the virus in a more vulnerable state when the engineered cells arrive.
Larger trials, longer follow-up, and a clearer picture of which patients are most likely to benefit all lie ahead. But for the first time in a controlled setting, a one-time cellular therapy has allowed some HIV patients to stop their medication and hold the virus at bay — and that door, once opened, is not easily closed.
In a Paris laboratory, researchers have taken an approach to HIV that sidesteps the traditional path of daily pills for life. They extracted immune cells from six patients, rewired them in a dish to hunt down the virus, multiplied them, and put them back. Two of those patients have now stopped taking antiretroviral drugs entirely—one for more than two years, another for nearly a year—and their viral loads remain undetectable or barely measurable. It is early work, a Phase 1 safety trial with a small group, but it marks a shift in how scientists are thinking about controlling one of the world's most persistent infections.
The therapy is called CAR-T, and it works by taking a patient's own T-cells—the immune system's foot soldiers—and engineering them to recognize and attack two specific entry points on HIV: the CD4 and CCR5 binding sites. Once the cells are modified and expanded in the laboratory, they are infused back into the patient's body, where they circulate and hunt. The virus, if left alone, replicates relentlessly and destroys the very cells meant to fight it, eventually leading to AIDS. But with these redesigned cells on patrol, the infection can be suppressed without the constant chemical pressure of antiretroviral drugs.
What makes this approach different from previous attempts at an HIV "cure" is accessibility. Earlier successes involved cancer patients who received bone marrow stem cells from donors carrying a rare genetic mutation—a natural resistance to HIV. That approach works, but it is available only to the tiny fraction of people who have a matching donor with that specific mutation. CAR-T, by contrast, uses each patient's own cells. "Our goal is to make these therapies affordable and accessible," said Dr. Boro Dropuli, executive director of Caring Cross, the nonprofit that collaborated with researchers at the University of California, San Francisco, UC Davis, and Case Western Reserve University Hospital on this trial.
The results so far are uneven but encouraging. Of the three patients who received the standard CAR-T dose, two have done remarkably well. One has maintained undetectable HIV levels for over two years without drugs. The other has done so for nearly a year. A third patient experienced an early rebound but then brought the virus under control to low but still-detectable levels. Three other trial participants received no chemotherapy beforehand—a preparation step normally used to clear space in the bone marrow for new cells—while another three received a lower dose. The trial was designed primarily to assess safety, not efficacy, which is why the numbers are small and the outcomes varied.
Dr. Steven Deeks, the study's lead investigator at UCSF, noticed something in the patients who fared best: they had been diagnosed and started on antiretroviral therapy quickly. "The two that have been off the longest and doing well were importantly diagnosed pretty quickly and put on therapy pretty quickly," he said. The reason matters. Antiretroviral drugs lock the virus in place, preventing it from mutating into new forms while also protecting the immune system from being ravaged. Early treatment, it seems, may leave the virus in a more vulnerable state when the CAR-T cells arrive to finish the job.
CAR-T is not new. It has been used for years to treat blood cancers, where it can persist in the body for long periods and trigger severe inflammatory responses in some patients. In this HIV trial, the side effects were gentler. Patients did not experience the harsh cytokine release syndrome—a dangerous flood of inflammatory molecules—that can occur in cancer treatment. That is partly because the viral burden in HIV patients is lower than the tumor burden in cancer patients, and the CAR-T cells do not need to mount as fierce an assault.
Researchers are now working to understand why some patients responded better than others, and which characteristics predict success. With 41 million people globally living with HIV and dependent on lifelong medication, even a therapy that works for a subset could reshape treatment. The next phase will require larger trials, longer follow-up, and careful attention to which patients are most likely to benefit. But the door has opened. For the first time in a controlled trial, a one-time cellular therapy has allowed some HIV patients to stop their drugs and keep the virus at bay.
Notable Quotes
Our goal is to make these therapies affordable and accessible— Dr. Boro Dropuli, executive director of Caring Cross
The two that have been off the longest and doing well were importantly diagnosed pretty quickly and put on therapy pretty quickly— Dr. Steven Deeks, lead investigator at UCSF
The Hearth Conversation Another angle on the story
Why does it matter that these patients were diagnosed and treated quickly?
Because antiretroviral drugs do something crucial—they freeze the virus in place. If you catch HIV early and start drugs immediately, the virus doesn't have time to mutate into many different forms. When the CAR-T cells arrive later, they're hunting a more stable target. It's like the difference between catching a fire in one room versus letting it spread through the whole house.
So this isn't a cure in the traditional sense?
Not yet, and maybe not ever in the way people imagine. But it's something different. A cure usually means the virus is gone. Here, the virus is still present, but the patient's own immune cells are controlling it without drugs. That's a meaningful distinction.
Why couldn't they use this approach for cancer patients too?
They already do, actually. CAR-T is standard for certain blood cancers now. But in cancer, the tumor burden is much higher, so the CAR-T cells have to work harder and persist longer. That intensity can cause severe side effects. In HIV, the viral load is lower, so the immune response is gentler.
What's the biggest unknown right now?
Why some patients respond well and others don't. The trial is too small to know if it's about genetics, the timing of diagnosis, the specific characteristics of their virus, or something else entirely. That's what the next phase of research has to answer.
If this works broadly, what changes?
Forty-one million people could stop taking pills every day for the rest of their lives. That's not just medical—it's freedom. No more pharmacy runs, no more side effects from daily drugs, no more stigma tied to visible medication. But we're a long way from knowing if it will work for most people.